headquartered at 7-9 Fashion Street, London, E1 6PX, United Kingdom. A
registered company in England and Wales: 09823909. | Terms and conditions
Our latest edition of Trends in Oncology Market Access & Pricing peers into the foggy future of healthcare to see what shapes to be made out.
With Oncology drug prices under intense and growing scrutiny, how are companies proving the value of their medicines?
With expert insights from Stephen Eck, VP, Astellas; Dan Ollendorf, Chief Scientific Officer, ICER; Ana Forsythe, MD, Purple Squirrel Economics and Jennifer Hinkel, Partner, McGivney Global Advisors, this 14-page report will provide you with:
An analysis of the routes companies are taking to prove the value of their oncology medicines
Details on how ICER wants to be ‘as open and transparent as possible’
How pharma companies can chart the fragmented payer landscape and become a more effective negotiating partner.
Be the first to uncover the latest Trends in Oncology and Market Access. Download your copy of Trends in Oncology Market Access & Pricing now >>>
Anthonia Kehinde Project Director – Oncology eyeforpharma Connect with me on Linkedin